Diaceutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Diaceutics şirketinin toplam hissedar öz sermayesi £38.7M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £45.4M ve £6.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£16.75m
Eşitlik	UK£38.74m
Toplam yükümlülükler	UK£6.69m
Toplam varlıklar	UK£45.43m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

May 30

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Jan 31

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Jan 28

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Jul 24

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Feb 04

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 31

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Nov 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DXRX 'nin kısa vadeli varlıkları ( £27.2M ) kısa vadeli yükümlülüklerini ( £5.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: DXRX şirketinin kısa vadeli varlıkları ( £27.2M ) uzun vadeli yükümlülüklerini ( £1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DXRX borçsuzdur.

Borcun Azaltılması: DXRX şirketinin 5 yıl önce borç/öz sermaye oranı 0.6% iken borcu yok.

Borç Kapsamı: DXRX un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: DXRX şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Diaceutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People Officer

Less than half of directors are independent

Diaceutics plc Announces Board Changes

Consensus EPS estimates upgraded to UK£0.016 loss

First half 2024 earnings: EPS and revenues exceed analyst expectations

Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024

Diaceutics PLC Launches Enhanced Rare-Disease Offering

Diaceutics PLC Announces Launch of PMx

Diaceutics plc Announces Board Changes

Now 21% overvalued after recent price rise

Consensus EPS estimates fall by 12%

Price target increased by 8.1% to UK£1.72

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

Independent Non-Executive Director recently bought UK£51k worth of stock

Full year 2023 earnings: Revenues in line with analyst expectations

Diaceutics PLC Launches Significant Upgrade to Its DXRX Platform

New minor risk - Market cap size

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Diaceutics PLC, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

Less than half of directors are independent

Consensus EPS estimates upgraded to UK£0.017 loss

First half 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profit margin trend

Diaceutics Announces Executive Changes

Diaceutics PLC Announces Executive Changes, Effective 1 October 2023

Diaceutics plc Launches Daily Alerts for Dxrx Platform

Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023

Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer Patients

First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)

Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022

Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX Platform

No independent directors

Executive Officer recently sold UK£198k worth of stock

Diaceutics PLC Announces Test Signal Launch and Contract Wins

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)

Diaceutics PLC Provides Earnings Guidance for the Year 2021

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

CFO & Executive Director recently sold UK£246k worth of stock

Full year 2020 earnings released

New 90-day low: UK£1.12

Diaceutics PLC Appoints Nikita Lynn as Vice President of Finance

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021

New 90-day high: UK£1.42

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Investor sentiment improved over the past week

Diaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020

Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx Platform

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing Standards

New 90-day low - UK£1.24

Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment Arm

New 90-day high - UK£1.75

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin